Fairvalue-Calculator Fairvalue-Calculator
EN DE

Liaoning He Eye Hospital Group (301103) Fair Value & Analysis

Healthcare · CN · Market cap 2.5B CNY

Price¥16.02
Fair Value¥7.57
Upside-52.7%
Quality95/100
Evidence: High Range ¥6.33 – ¥8.82

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Liaoning He Eye Hospital Group (301103) currently trades at ¥16.02, while our model-based Fair Value estimate is ¥7.57 — implying the stock looks roughly 52.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Liaoning He Eye Hospital Group Co., LTD. provides ophthalmic specialist diagnosis, treatment, and optometry services to patients with eye diseases. It offers cataract diagnosis and treatment, refractive error surgical correction, vitreoretinal diagnosis and treatment, other surgical diagnosis and treatment services, etc. The company also provides refractive cataracts, LASIK surgery, myopia prevention, medical fitting, diabetic retinopathy, dry eyes and cornea, gene diagnosis, and comprehensive eye disease solutions. Liaoning He Eye Hospital Group Co., LTD. was founded in 1995 and is based in Shenyang, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Liaoning He Eye Hospital Group (301103) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥7.57 versus a price of ¥16.02 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301103?
Our 21-model fair value for Liaoning He Eye Hospital Group is ¥7.57 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥16.02.
What is the quality score of 301103?
Liaoning He Eye Hospital Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.